PolyPid Ltd. Logo

PolyPid Ltd.

Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.

PYPD | US

Overview

Corporate Details

ISIN(s):
IL0011326795
LEI:
Country:
United States of America
Address:
18 HASIVIM STREET, 4959376 PETACH TIKVA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PolyPid Ltd. is a late-stage biopharmaceutical company focused on developing and commercializing locally administered therapies to improve surgical outcomes. The company's proprietary PLEX™ (Polymer-Lipid Encapsulation) technology is a drug delivery platform designed for the localized, controlled, and prolonged release of therapeutic agents. Its lead product candidate, D-PLEX₁₀₀, is in advanced clinical development for the prevention of surgical site infections (SSIs) following abdominal colorectal surgery. PolyPid is also leveraging its PLEX platform to expand its pipeline into other high-value markets, including oncology and metabolic diseases, with a long-acting GLP-1 receptor agonist delivery system for the diabetes and weight loss market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PolyPid Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PolyPid Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PolyPid Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Developing protein degradation medicines to treat cancer and autoimmune diseases.
United States of America
NRIX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary
NUTEX
NutriBand Inc. Logo
Develops abuse-deterrent transdermal patches to make potent drug delivery safer.
United States of America
NTRB
Nuvalent, Inc. Logo
Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.
United States of America
NUVL
Nuvation Bio Inc. Logo
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America
NUVB
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan
4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland
OBSN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America
OCUL

Talk to a Data Expert

Have a question? We'll get back to you promptly.